FDA's Gutierrez Provides Additional Clarity Regarding Oversight of DTC Genomics Firms

"The fact is that Pathway's bold move to make themselves noticed achieved its end and brought them to our attention," an FDA official told Pharmacogenomics Reporter.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.